Following treatment with the P2Y12 antagonist [cangrelor, 1 μM], the P2Y1 antagonist [MRS2179, 10 μM] or the ADP/ATPase (apyrase, 10 units/ml), platelet activation in the presence of 59M ovarian cancer cells was significantly diminished [1 μM Cangrelor - 92.4±0.64% inhibition, p<0.001; 10 μM MRS2179 – 71.4±10.52% inhibition, p = 0.01; 10 units/ml apyrase, 91.8±3.7% inhibition, p<0.001]. Here, P2RY1 is linked to ovarian cancer.